Most active ALDEI.PA Deinove SA (EURONEXT) 10 Mar 2026: 13.01M shares, what to watch

ALDEI.PA stock was one of the most active names on EURONEXT at market close on 10 Mar 2026. Volume reached 13,014,939 shares and the last trade printed at EUR 0.0265. Traders showed above-average appetite with relative volume 2.17x versus the 30‑day average. The intraday range was EUR 0.0231–0.0321, leaving momentum and liquidity as the immediate story for investors.

ALDEI.PA stock: intraday action and volume drivers

Deinove SA (ALDEI.PA) closed the EURONEXT session with unusually high turnover, matching the most active screen strategy. Volume was 13,014,939 versus an average of 5,992,347, which pushed the relative volume to 2.17 and amplified price moves. This trading pattern signals short-term interest from retail and speculative desks looking at low‑priced biotech names.

Price, valuation and key ratios for ALDEI.PA stock

The last price was EUR 0.0265 with a 52‑week range of EUR 0.0062–0.4360. Market cap stood at EUR 1,134,989 and shares outstanding are 42,829,773. Reported metrics show EPS ‑0.24 and a trailing PE that is negative due to losses. Price to sales is 3.09 and the current ratio is 1.36, reflecting thin revenue and limited liquidity on the balance sheet.

Pipeline, partners and revenue context for ALDEI.PA stock

Deinove operates in Biotechnology with clinical and cosmetic ingredients. Its antibiotic candidate DNV3837 is in Phase II and the company licenses active ingredients for cosmetics and feed. Partnerships include bioMerieux and Institut Pasteur, which provide validation but not immediate revenue scale. Revenue per share is modest at EUR 0.01 and the company remains development‑stage.

Technical picture and Meyka Stock Grade for ALDEI.PA stock

Technically, ALDEI.PA sits above its 50‑day average of EUR 0.02315 but well below the 200‑day average of EUR 0.11427, showing mixed momentum. Meyka AI rates ALDEI.PA with a score out of 100: 65.07 (Grade B, Suggestion: HOLD). This grade factors S&P 500 and sector comparisons, financial growth, key metrics, and analyst signals. Grades are informational only and not investment advice.

Risks, catalysts and sector context for ALDEI.PA stock

Primary risks include clinical trial outcomes, thin liquidity and a tiny market cap that increases volatility. Catalysts to watch are Phase II readouts, licensing deals, or larger partner announcements. Within the Healthcare sector, biotech names trade on binary outcomes; Deinove’s current metrics leave it sensitive to news flow and sector sentiment.

Trading notes and what active traders should watch

Given the high intraday volume, watch order book depth and bid‑ask spread. A high relative volume day like this can precede follow‑through if a tangible catalyst appears. For EURONEXT traders, monitor block trades and any press releases on the company site Deinove and filings aggregated by data providers FinancialModelingPrep.

Final Thoughts

ALDEI.PA stock closed as one of the most active small‑cap names on EURONEXT on 10 Mar 2026, trading 13,014,939 shares at EUR 0.0265. The move reflects speculative interest rather than an earnings or major licensing surprise. Fundamentals show negative EPS ‑0.24, a small market cap of EUR 1,134,989, and thin revenue per share. Meyka AI’s forecast model projects a 12‑month base price of EUR 0.0400, implying an upside of about 50.94% versus the current EUR 0.0265. We also model a conservative downside scenario near EUR 0.0150, which implies a potential decline of 43.40%. Forecasts are model‑based projections and not guarantees. Active investors should balance the binary biotech risk with position sizing and watch trial milestones or licensing updates for directional conviction. Meyka AI provides this as an AI‑powered market analysis snapshot, not investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.